Use of a maturity model for facilitating the introduction of CAR T-cell therapy—Results of the START CAR-T project

INTRODUCTION: Chimeric antigen receptor (CAR) T-cell therapies are novel immunotherapies for the treatment of hematologic malignancies. They are administered in specialized centers by a multidisciplinary team and require the careful coordination of all steps involved in manufacturing and using cellu...

Descripción completa

Detalles Bibliográficos
Autores principales: Bramanti, Stefania, Carrabba, Matteo G., Di Rocco, Alice, Fabris, Elena, Gastaldi, Luca, Locatelli, Paolo, Tisi, Maria Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AboutScience 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768606/
https://www.ncbi.nlm.nih.gov/pubmed/36628303
http://dx.doi.org/10.33393/grhta.2022.2340

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768606/
https://www.ncbi.nlm.nih.gov/pubmed/36628303
http://dx.doi.org/10.33393/grhta.2022.2340

Ejemplares similares